Literature DB >> 263394

Migraine and the mitral valve prolapse syndrome.

G I Litman, H M Friedman.   

Abstract

We believe there is a significant association between migraine and the prolapse mitral valve syndrome. Propranolol is the drug of choice in these patients for the treatment and prevention of migraine. Increased platelet aggregability may be the common pathophysiologic mechanism as relates to emboli from the valve and possibly in strokes related to migraine. Recognition of the association of the two syndromes will result in appropriate subacute bacterial endocarditis prophylaxis for patients at risk as well as prevention of improper medication to those patients with migraine who are at risk for stroke.

Entities:  

Mesh:

Year:  1978        PMID: 263394     DOI: 10.1016/0002-8703(78)90197-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Vascular headache.

Authors:  K L Kumar; T G Cooney
Journal:  J Gen Intern Med       Date:  1988 Jul-Aug       Impact factor: 5.128

2.  Ischemic strokes and migraine.

Authors:  M G Bousser; J C Baron; J Chiras
Journal:  Neuroradiology       Date:  1985       Impact factor: 2.804

Review 3.  The migraine association with cardiac anomalies, cardiovascular disease, and stroke.

Authors:  Todd J Schwedt
Journal:  Neurol Clin       Date:  2009-05       Impact factor: 3.806

4.  Amaurosis fugax in young people.

Authors:  F O'Sullivan; M Rossor; J S Elston
Journal:  Br J Ophthalmol       Date:  1992-11       Impact factor: 4.638

5.  Increased prevalence of mitral valve prolapse in patients with migraine.

Authors:  J D Spence; D G Wong; L J Melendez; P M Nichol; J D Brown
Journal:  Can Med Assoc J       Date:  1984-12-15       Impact factor: 8.262

6.  Mitral valve billow and prolapse: a brief review at 45 years - with reference to : mitral valve billowing and prolapse : perspective at 25 years.

Authors:  I W Obel
Journal:  Cardiovasc J Afr       Date:  2009 Jan-Feb       Impact factor: 1.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.